• Wondering whether MannKind's current share price lines up with its underlying worth, or if the market is mispricing the stock.
• The stock last closed at US$3.38, with gains of 13.0% over the past 7 days and 25.2% over the past month, while still showing a decline of 39.6% year to date and 18.0% over the past year.
• Recent coverage around MannKind has focused on its position in the Biotechs space and on how investors are assessing its long term prospects and risks. This context helps explain why the share price has seen both periods of recovery and longer term weakness.
• MannKind currently holds a valuation score of 5/6. The rest of this article will break down how different valuation approaches arrive at that result, before finishing with a broader way to think about what the stock might be worth.

Approach 1: MannKind Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting the company’s future cash flows and then discounting those back to today’s value using a required rate of return.

For MannKind, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow shows an outflow of about $1.27 million, so the company is currently not generating positive free cash flow. Analysts and internal estimates then project free cash flow turning positive and reaching $80 million by 2030, with detailed year by year projections supplied through 2035. Simply Wall St notes that analyst inputs generally cover only the next few years and longer term numbers are extrapolated from those inputs.

When all those projected cash flows are discounted back, the model arrives at an estimated intrinsic value of about $4.73 per share. Compared with the recent share price of $3.38, this particular DCF output suggests MannKind trades at about a 28.5% discount, indicating that the stock may be undervalued on this measure.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests MannKind is undervalued by 28.5%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.

Approach 2: MannKind Price vs Sales

For companies where earnings are not yet the main focus, the P/S ratio can be a practical way to think about valuation, because it compares what you are paying for each dollar of revenue rather than each dollar of profit.

Growth expectations and risk still matter here, since investors usually accept a higher P/S ratio when they expect stronger revenue growth and see fewer risks, while lower growth expectations and higher uncertainty tend to justify a lower multiple.

MannKind currently trades on a P/S ratio of 2.89x. This sits below the Biotechs industry average of 10.66x and below the peer group average of 4.27x. Simply Wall St also calculates a proprietary “Fair Ratio” of 4.76x for MannKind, which reflects factors such as earnings growth expectations, industry, profit margin, market cap and company specific risks.

This Fair Ratio can be more informative than a simple comparison with peers or the industry, because it adjusts for MannKind’s own characteristics instead of assuming it should trade exactly in line with averages.

Comparing the current 2.89x P/S ratio with the 4.76x Fair Ratio suggests the stock screens as undervalued on this measure.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your MannKind Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives let you attach a clear story about MannKind to the numbers by linking your view on its products, risks and competitive position to explicit forecasts for revenue, earnings and margins, then turning that into a fair value you can compare with the current share price. All of this happens inside the Simply Wall St Community page, where Narratives update automatically when fresh news or earnings land. There you can see, for example, a cautious MannKind Narrative that lines up with a Fair Value of US$4.75 per share alongside a more optimistic Narrative closer to US$8.00 per share, helping you decide which story you believe and what that implies for whether the stock looks expensive or cheap to you today.

Do you think there's more to the story for MannKind? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.